The Effects of Paroxetine on the Pharmacokinetics of Paliperidone Extended-release Tablets

Abstract

Introduction: Co-morbid medical and psychiatric conditions are common in individuals with schizophrenia. As such, selecting antipsychotic medications with a low potential for drug−drug interactions (DDIs) is crucial, as many are extensively metabolized by hepatic cytochrome P450 (CYP) isozymes.

Methods: This randomized, crossover study examined the effects of paroxetine (a potent CYP2D6 inhibitor) on the pharmacokinetic parameters of a single dose of the novel antipsychotic agent, paliperidone extended-release tablets (paliperidone ER), in healthy subjects.

Results: The mean C_max and AUC of paliperidone were slightly higher and paliperidone clearance was slightly lower following co-administration of paliperidone ER with paroxetine. There was a ratio of geometric treatment means of 116.48% for AUC_∞ [90% CI: 104.49–129.84]. However, the increase in total exposure to paliperidone was not considered clinically relevant. The incidence of adverse events was lower when subjects received the combination of paliperidone ER and paroxetine compared with paroxetine alone.

Discussion: Results suggest that no clinically relevant pharmacokinetic interaction occurs when paroxetine and paliperidone ER are co-administered and, therefore, initiation or discontinuation of concomitant treatment with CYP2D6-inhibiting drugs does not appear to warrant an adjustment in paliperidone ER dosage.

References

• 1 Abilify . United States Prescribing Information. http://wwwbmscom/products/data/index , Accessed November 2006
• 2 Aursnes I, Gjertsen MK. Common adverse events associated with an SSRI: meta-analysis of early paroxetine data.  Pharmacoepidemiol Drug Saf. 2008;  17 707-713
• 3 Barnhill J, Susce MT, Diaz FJ. et al . Risperidone half-life in a patient taking paroxetine – a case report.  Pharmacopsychiatry. 2005;  38 223-225
• 4 Berecz R, Llerena A, de la Rubia A. et al . Relationship between risperidone and 9-hydroxy-risperidone plasma concentrations and CYP2D6 enzyme activity in psychiatric patients.  Pharmacopsychiatry. 2002;  35 231-234
• 5 Carney CP, Jones L, Woolson RF. Medical comorbidity in women and men with schizophrenia: a population-based controlled study.  J Gen Intern Med. 2006;  21 1133-1137
• 6 Castberg I, Spigset O. Effects of comedication on the serum levels of aripiprazole: evidence from a routine therapeutic drug monitoring service.  Pharmacopsychiatry. 2007;  43 107-110
• 7 Chwastiak LA, Rosenheck RA, MacEvoy JP. et al . Interrelationships of psychiatric symptom severity, medical comorbidity, and functioning in schizophrenia.  Psychiatr Serv. 2006;  57 1102-1109
• 8 Cleton A, Rossenu S, Boom S. et al . Evaluation of the pharmacokinetics of paliperidone extended-release tablets in healthy elderly subjects.  Clin Pharmacol Ther. 2007;  81 S62
• 9 Clozapine . United States Prescribing Information. http://http//www.pharma.us.novartis.com/product/pi/pdf/clozaril.pdf , Accessed May 2005
• 10 Conley RR, Ascher-Svanum H, Zhu B. et al . The burden of depressive symptoms in the long-term treatment of patients with schizophrenia.  Schizophr Res. 2007;  90 186-197
• 11 Conley RR, Kelly DL. Drug-drug interactions associated with second-generation antipsychotics: considerations for clinicians and patients.  Psychopharmacol Bull. 2007;  40 77-97
• 12 Dailly E, Urien S, Chanut E. et al . Evidence from a population pharmacokinetics analysis for a major effect of CYP1A2 activity on inter- and intraindividual variations of clozapine clearance.  Prog in Neuro-Psychopharmacol Biol Psychiatry. 2002;  26 699-703
• 13 Davidson M, Emsley R, Kramer M. et al . Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study.  Schizophr Res. 2007;  93 117-130
• 14 Leon J de, Susce MT, Pan RM. et al . The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation.  J Clin Psychiatry. 2005;  66 15-27
• 15 Diaz FJ, Santoro V, Spina E. et al . Estimating the size of the effects of co-medications on plasma clozapine concentrations using a model that controls for clozapine doses and confounding variables.  Pharmacopsychiatry. 2008;  43 81-91
• 16 Doude van Troostwijk LJ, Koopmans RP, Vermeulen HD. et al . CYP1A2 activity is an important determinant of clozapine dosage in schizophrenic patients.  Eur J Pharm Sci. 2003;  20 451-457
• 17 Guidance for industry . In vivo drug metabolism/drug interaction studies – study design, data analysis and recommendations for dosing and labeling US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER) November 1999. http://wwwfdagov/cber/guidelineshtm
• 18 Invega Prescribing Information. Janssen Pharmaceuticals, Titusville, NJ, USA. http://wwwfdagiov/cder/foi/label/2006/021999lblpdf , Accessed January 2007
• 19 Kane J, Canas F, Kramer M. et al . Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial.  Schizophr Res. 2007;  90 147-161
• 20 Kirschbaum KM, Muller MJ, Malevani J. et al . Serum levels of aripiprazole and dehydroaripiprazole, clinical response and side effects.  World J Biol Psychiatry. 2008;  9 (3) 212-218
• 21 Kramer M, Simpson G, Maciulis V. et al . Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study.  J Clin Psychopharmacol. 2007;  27 6-14
• 22 Mallet CR, Lu Z, Mazzeo JR. A study of ion suppression effects in electrospray ionization from mobile phase additives and solid-phase extracts.  Rapid Commun Mass Spectrom. 2004;  18 49-58
• 23 Marder SR, Kramer M, Ford L. et al . Efficacy and Safety of Paliperidone Extended-Release Tablets: Results of a 6-Week, Randomized, Placebo-Controlled Study.  Biol Psychiatry. 2007;  62 1363-1370
• 24 Owen RT. Extended-release paliperidone: efficacy, safety and tolerability profile of a new atypical antipsychotic.  Drugs Today (Barc). 2007;  43 249-258
• 25 Paroxetine Prescribing Information . http://http//us.gsk.com/products/assets/us_paxil.pdf , Accessed October 2008.
• 26 Preskorn SH, Greenblatt DJ, Flockhart D. et al . Comparison of duloxetine, escitalopram, and sertraline effects on cytochrome P450 2D6 function in healthy volunteers.  J Clin Psychopharmacol. 2007;  27 28-34
• 27 Saito M, Yasui-Furukori N, Nakagami T. et al . Dose-dependent interaction of paroxetine with risperidone in schizophrenic patients.  J Clin Psychopharmacol. 2005;  25 527-532
• 28 Seedat S, Fritelli V, Oosthuizen P. et al . Measuring anxiety in patients with schizophrenia.  J Nerv Ment Dis. 2007;  195 320-324
• 29 Spina E, Avenoso A, Facciola G. et al . Plasma concentrations of risperidone and 9-hydroxyrisperidone during combined treatment with paroxetine.  Ther Drug Monit. 2001;  23 223-227
• 30 Spina E, Avenoso A, Salemi M. et al . Plasma concentrations of clozapine and its major metabolites during combined treatment with paroxetine or sertraline.  Pharmacopsychiatry. 2000;  33 213-217
• 31 Spina E, Leon J de. Metabolic drug interactions with newer antipsychotics: a comparative review.  Basic Clin Pharmacol Toxicol. 2007;  100 4-22
• 32 Vermeir M, Boom S, Naessen I. et al . Absorption, metabolism and excretion of a single oral dose of 14C-paliperidone 1 mg in five healthy male subjects.  Clin Pharmacol Ther. 2006;  79 80

1 Current address: Pharma-Plus, Rucphen, The Netherlands.

2 Current address: Genentech, Inc, South San Francisco, California, USA.

Correspondence